Eli Lilly and Company (LLY) — closed signal from May 24, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 22, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$990.00 – $1,035.00Entry zone — fair-value band
$1,065.00Published — price the day we called it
$1,160.85Target — the price the thesis aimed for
$1,292.65Peak — highest point inside the window, not a realized return
$1,255.40Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 12 days.
Peak price
$1,292.65
peak on August 19, 2026 — not a realized returnPeak gain
+21.4%
peak, from the publication priceWindow close
$1,255.40
end-of-window price, context onlyDays to target
12
Window
May 24, 2026 – August 22, 2026
The thesis — published May 24, 2026
Predicted growth
+9%
over the measurement windowTarget price
$1,160.85
the price the thesis aimed forEntry zone
$990.00 – $1,035.00
the fair-value band we waited forPrice at publication
$1,065.00
published May 24, 2026Confidence
67%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Eli Lilly looks strong because new trial results for its obesity drug expand the sales runway. The retatrutide update reinforces its leadership in a key growth area. Near-term, the stock is extended after recent gains, so the immediate upside is less clear. Debt levels also reduce overall conviction for now.
Primary drivers
- Retatrutide trial strengthens leadership in obesity drugs
- Diabetes and obesity businesses expected to keep growing
- Consistent earnings beats show reliable execution
- Recent price run means timing for entry matters
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.